Editions

An estimated 33,000 people die in the European Union every year as a result of being infected with antibiotic-resistant germs. The number of deaths associated with antimicrobial resistance worldwide is estimated to be more than 5 million per year. New antibiotics urgently need to be developed, but this is often not profitable for companies. This article discusses a dynamic funding model that would make it more attractive for firms to develop new antibiotics.

Directly paid healthcare costs in Switzerland decrease as a share of income as income increases, whereas in other countries it is typically the other way round. This is due not to rising healthcare costs but to the way healthcare expenditure is funded.